Bottom
Line: Bacterial load was significantly higher in pancreatic tumor samples from patients with pancreatic ductal adenocarcinoma compared with pancreatic tissue from normal individuals, and in studies using mice, eliminating certain «bad» bacteria slowed the growth of pancreatic cancer, reversed
immune suppression, and upregulated the
immune checkpoint protein PD1.
Led by Leena Gandhi, MD, PhD, associate professor of medicine and director of thoracic medical oncology, researchers from the KEYNOTE - 021 study demonstrated for the first time that combining an
immune checkpoint inhibitor — in this case, pembrolizumab — with a platinum - doublet chemotherapy regimen might be more effective than chemotherapy alone as first -
line treatment for advanced, non-squamous NSCLC.